Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Healthy subjects~* Body Mass Index (BMI) of 18 to 30 kg/m2~* Ages 18 to 45 years, including~* Women of childbearing potential (WOCBP) on acceptable contraception and with negative pregnancy test and not breastfeeding~Exclusion Criteria:~* History or evidence of coagulopathy~* History or evidence of thrombosis such as deep vein thrombosis or other thromboembolic disease or having a first degree relative under 50 years of age with a history of thromboembolic disease~* Any significant acute or chronic medical illness or relevant trauma~* Any major surgery within 4 weeks of dosing (prior to dosing) or planned within 2 weeks after completion of the study~* History of heavy menstrual bleeding that has produced anemia within the past 1 year~* Current symptomatic or recent gastrointestinal disease or surgery that could impact the absorption of study drug~* History of smoking within 1 month prior to dosing~* Recent history (within 6 months of dosing) of pregnancy~* Use of hormonal contraceptives~* Exposure to any investigational drug or placebo within 4 weeks of study drug administration~* Use of any agent, including but not limited to Aspirin, Nonsteroidal anti-inflammatory drugs (NSAIDs), Anticoagulants, Fish oil capsules, Gingko, etc, that are known to increase the potential for bleeding, within 2 weeks prior to dosing~* History of any severe drug allergy including allergy to Heparin or history of Heparin-induced thrombocytopenia, hypersensitivity to PCCs or Factor Xa inhibitors, or history of allergy to human blood plasma derived products; history of any adverse drug reaction to Anticoagulants or Antiplatelet agents that resulted in excessive bleeding requiring medical intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A: Apixaban + Placebo (Saline solution) (Type: EXPERIMENTAL): Apixaban 10 mg Tablet orally \[Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)\] followed 3hr later by Saline solution (placebo) 0 IU/kg infusion for 30 min Intravenously
- Treatment B: Apixaban + Cofact (4-Factor PCC) (Type: EXPERIMENTAL): Apixaban 10 mg Tablet orally \[Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)\] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
- Treatment C: Apixaban + Beriplex P/N (4-Factor PCC) (Type: EXPERIMENTAL): Apixaban 10 mg Tablet orally \[Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)\] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).